NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
IRLAB Therapeutics AB (publ) (ST: IRLAB-A)
IRLAB-A Technical Analysis
4
As on 22nd Nov 2024 IRLAB-A STOCK Price closed @ 13.10 and we RECOMMEND Buy for LONG-TERM with Stoploss of 10.01 & Strong Buy for SHORT-TERM with Stoploss of 7.94 we also expect STOCK to react on Following IMPORTANT LEVELS. |
IRLAB-ASTOCK Price
Open | 12.90 | Change | Price | % |
High | 13.20 | 1 Day | 1.00 | 8.26 |
Low | 12.35 | 1 Week | -1.05 | -7.42 |
Close | 13.10 | 1 Month | 1.15 | 9.62 |
Volume | 14825 | 1 Year | 5.48 | 71.92 |
52 Week High 19.60 | 52 Week Low 5.90 |
ST Sweden Most Active Stocks
TANGI | 0.00 | % |
FING-B | 0.08 | 0.00% |
SBB-B | 4.00 | 1.78% |
LUNE | 21.97 | 6.65% |
SNM | 0.88 | 2.33% |
DIABIO | 0.03 | 0.00% |
WYLD | 0.02 | 0.00% |
NIBE-B | 45.75 | 1.87% |
HDW-B | 0.00 | % |
EURA | 0.01 | 0.00% |
ST Sweden Top Gainers Stocks
ST Sweden Top Losers Stocks
IRLAB-A Daily Charts |
IRLAB-A Intraday Charts |
Whats New @ Bazaartrend |
IRLAB-A Free Analysis |
|
IRLAB-A Important Levels Intraday
RESISTANCE | 14.74 |
RESISTANCE | 14.21 |
RESISTANCE | 13.89 |
RESISTANCE | 13.56 |
SUPPORT | 12.64 |
SUPPORT | 12.31 |
SUPPORT | 11.99 |
SUPPORT | 11.46 |
IRLAB-A Forecast November 2024
4th UP Forecast | 16.07 |
3rd UP Forecast | 15.12 |
2nd UP Forecast | 14.53 |
1st UP Forecast | 13.94 |
1st DOWN Forecast | 12.26 |
2nd DOWN Forecast | 11.67 |
3rd DOWN Forecast | 11.08 |
4th DOWN Forecast | 10.13 |
IRLAB-A Weekly Forecast
4th UP Forecast | 15.87 |
3rd UP Forecast | 14.98 |
2nd UP Forecast | 14.43 |
1st UP Forecast | 13.88 |
1st DOWN Forecast | 12.32 |
2nd DOWN Forecast | 11.77 |
3rd DOWN Forecast | 11.22 |
4th DOWN Forecast | 10.33 |
IRLAB-A Forecast2024
4th UP Forecast | 41.27 |
3rd UP Forecast | 32.24 |
2nd UP Forecast | 26.65 |
1st UP Forecast | 21.07 |
1st DOWN Forecast | 5.13 |
2nd DOWN Forecast | -0.45 |
3rd DOWN Forecast | -6.04 |
4th DOWN Forecast | -15.07 |
IRLAB Therapeutics AB (publ) ( ST Sweden Symbol : IRLAB-A )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
IRLAB-A Other Details
Segment | EQ | |
Market Capital | 2191544576.00 | |
Sector | Healthcare | |
Industry | Biotechnology | |
Offical website | > echo $website ; ?> |
IRLAB-A Address
IRLAB-A Latest News
IRLAB-A Business Profile
IRLAB Therapeutics AB (publ), a research and development company, develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; Pirepemat, which is in phase II clinical trial for the treatment of Postural dysfunction. It also develops IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing. In addition, the company develops P003, a research project that develops drugs as a substitute of levodopa for Parkinson's disease. The company is based in Gothenburg, Sweden. Address: Arvid Wallgrens Backe 20, Gothenburg, Sweden, 413 46
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service